fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Markets Pause But Novavax, Sunrun & Tesla Fly Ahead

By John F. Heerdink, Jr.

The markets took a little breather today after having a nice run as some are pointing again that it may be overextended and/or that further fears of the coronavirus cases are surging and may cause further slowing of the economy. 10 out of eleven sectors finished in the red today as the lone holdout, the consumer staples sector, finished in positive territory up 1%. The energy sector down 3.2% & the financials sector down 2.1% were the co-leaders in the decline. The Nasdaq closed at down .86% closing at 10,343.89. The S&P 500 also lower down 1.08% closing at 3,145.32. The Dow closed down 1.51% at 25,890.18 and the Russell 2000 down 1.86% closing at 1,416.00. 

One of the big stories of the day came from Novavax (NVAX) which closed at $104.56/share up a considerable 31.6% as it announced it received a monster $1.6B investment from the good ole USA’s federal government to assist in expediting its COVID-19 vaccine candidate development and delivery process. Another came from Sunrun (RUN) which closed $26.17/share up 22.63% after announcing the acquisition of fellow solar power firm Vivant Solar for approximately $3.2B.

The heavily weighted FAANG stocks also took a the day off and overall closed lower as follows: Facebook (FB) closed at $240.86/share up .24%, Amazon (AMZN) closed at $3,000.12/sharedown 1.86%,  Apple (AAPL) closed at $372.69/share down .31%, Netflix (NFLX) lost .13% closing at $493.16/share & Alphabet (GOOG) closed at $1,485.18/share down .70%.

On the macroeconomic front, we learned that the Job Openings report (JOLTS) confirmed that job openings rose to 5.397M in May further reflecting the reopening measures were at work. 

Gold closed above the $1800 mark again at $1,802 (+11) & silver prices closed at $18.53/oz (+.01). North American silver and gold producer Hecla Mining Company (HL) closed at $3.39/share up 3.67% while First Majestic Silver (AG) closed at $9.68/share up 1.89%.

Oil prices bumped up .2% closing at above $40.60/bbl. Energy leaders Chevron (CVX) closed at $86.31/share down by 2.55%, Exxon (XOM) closed at $43.24/share down 2.59% & highly leveraged Occidental Petroleum Corporation (OXY) closed at $17.15/share down 5.67%. Midstream player, Enterprise Products Partners (EPD), closed trading at $17.62/share, flat on the day, and currently sporting at an attractive $1.78/share dividend or 10.10%. 

The 2-yr US treasury yield closed flat at .16% while the 10-yr yield dropped by 3 basis points to .65%. The U.S. Dollar Index strengthened by .3% to end at 97. 

MOVERS 

Here’s a couple of other equities that moved significantly higher today that included monster moves from companies within the electric car sector that we highlighted recently:

  • Electric car companies had another good day today as
    • Tesla (TSLA) closed at $1,389.86/share up 1.33% after establishing a new record high of $1429.50, a move that came after recently exceeding delivery expectations and even one analyst stating that it was the next $100B company as an army of investors continue to pile in,
    • Chinese concern, Nio Inc. (NIO) closed at $13.22/share up another 14.86%, &
    • Little Austin, TX firm, Aryo, Inc. (AYRO), added another 10.84% and yesterday’s 63.61% jump closing at $5.93/share today. AYRO reported before the market yesterday that they had completed factory expansion to handle up to 600 electric vehicles a month and then announced during the trading session that they were raising capital via a $15M registered direct offering at $4.75/share.

TOMORROW

The macroeconomic calendar will produce the Consumer Credit Report for May & the weekly MBA Mortgage Applications Index.

WATCH LIST

  • Shares of Fate Therapeutics (FATE) closed at $37.52/share up 1.96% up its 52-week low of $12.59 and after establishing a new all-time high of $38.52/share. On June 11th, FATE recently announced that it had closed an underwritten public offering of 7,108,796 shares of its common stock, which included 927,324 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $28.31 per share. Aggregate gross proceeds from this offering, including the exercise of the option, were approximately $201.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. Are you still invested in Fate after meeting them via this newsletter and attending meetings over the last couple of years when it was in the $3-4 range?… Recently, Fate announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. FT538 is an off-the-shelf natural killer (NK) cell cancer immunotherapy that is derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three functional components to enhance innate immunity: a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor; an IL-15/IL-15 receptor fusion (IL-15RF); and the elimination of CD38 expression. The Company plans to initiate a clinical investigation of three once-weekly doses of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma.
  • Shares of Neubase Therapeutics (NBSE) closed at $8.83/share up 1.15%. RBC Capital Markets recently initiated coverage of NBSE today with an Outperform, Speculative Risk rating & a $16 price target. As we have been stating, we are following Neubase Therapeutics (NBSE) for a number of reasons including its development of a modular antisense peptide nucleic acid (PNA) platform with the capability to address rare genetic disease caused by mutant proteins with a single, cohesive approach. NBSE was added to the Russell 3000 last Friday.

  • Shares of Stereotaxis, Inc. (STXS) closed at $4.38/share down .45%. The 52-week range is $1.70 – $5.82/share. The global leader in innovative robotic technologies for the treatment of cardiac arrhythmias continues to gain traction after their webcast symposium was held this weekend where they held a live broadcast of their bi-directional TeleRobotic procedures with physicians navigating catheters from hospitals more than 1700 km apart. They were recently added to the Rusell 2000 and the Russell 3000 indexes.
  • Shares of Aduro (ADRO) closed at $2.62/share today up another 2.34%. On June 2nd, Aduro Biotech, Inc.(ADRO) and Chinook Therapeutics, Inc., a privately-held clinical-stage biotechnology company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, today announced that the companies have entered into a definitive merger agreement pursuant to which Aduro will acquire all of the outstanding capital stock of Chinook in exchange for shares of Aduro common stock representing approximately 50 percent of Aduro’s outstanding common stock immediately following completion of the transaction. The combined company is expected to have approximately $200 million in cash, cash equivalents, and marketable securities at closing, including $25 million in additional financing committed by Chinook’s existing investors. Following closing, which is expected to occur in the second half of 2020, Aduro will be renamed Chinook Therapeutics, Inc., and is expected to trade on the Nasdaq Global Market under the ticker symbol “KDNY”. Yesterday, ADRO announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors. “We are thrilled to have dosed the first patient with IgA nephropathy in the Phase 1 clinical study of our investigational anti-APRIL antibody, BION-1301,” said Dimitry S.A. Nuyten, M.D., Ph.D., chief medical officer of Aduro. “The data Aduro recently presented from Parts 1 and 2 of this study in healthy volunteers at the 57th ERA-EDTA Virtual Congress indicated BION-1301 was well-tolerated, had a half-life of approximately 33 days, achieved over 90% target engagement with a single 450 mg dose of BION-1301 and demonstrated dose-dependent and durable reductions in IgA and IgM levels, and to a lesser extent, IgG levels. We look forward to hopefully replicating this effect in addition to exploring BION-1301’s disease-modifying potential in patients with IgA nephropathy in Part 3 of the ongoing Phase 1 clinical study.”
  • Shares of INVO Bioscience (INVO) closed at $3.80/share up 5.69%. Last week, INVO announced the second closing of its convertible note and unit purchase option private placement. The Company had previously conducted the first closing on May 15, 2020. The combination of both closings resulted in gross proceeds of $3,093,640 (of which $2,950,000 was received in cash and $143,640 resulted from cancellation of indebtedness. Steve Shum, Chief Executive Officer of INVO stated, “We appreciate the financial support from our investors as we execute our mission toward increasing patient access and treatment within the infertility marketplace through our revolutionary INVOcell device, an affordable, scalable and effective solution. We continue to push forward with our global commercialization efforts with our major U.S. partner, along with our current partners in Africa, Eurasia, and India; and are pursuing many other key regions and partners in Central and South America, Europe, and Asia Pacific.” On Monday, there was an 8k filed which confirmed a final third closing on the funding in the aggregate original principal amount of $401,200. The Company recently that it had effected a 1-for-20 reverse stock split reducing the amount of issued and outstanding common shares to approximately 7.89 million common shares. The reverse split was previously approved by the Company’s Board of Directors pursuant to the authority granted by the Company’s stockholders at the Company’s annual shareholder meeting held on December 16, 2019. On Thursday last week, Birmingham, Alabama-based America Institute of Reproductive Medicine (AIRM) published a report highlighting the success achieved in their practice utilizing INVOcell. “The AIRM clinic became an early adopter and advocate for the use of INVOcell shortly after we received FDA-clearance. We appreciate their willingness to share their story of that successful implementation of INVOcell within their clinical practice, which highlights important aspects of our INVOcell technology solution,” stated Steve Shum, CEO of INVO Bioscience. You can review the report here.
  • Aryo, Inc. (AYRO),  jumped another 10.84% closing at $5.93/share. On Monday, AYRO reported that they had completed a factory expansion to handle up to 600 electric vehicles a month and announced a $15M registered direct offering at $4.75/share.
  • TransEnterix (TRXC) closed trading at $.3971/share up 20.44% after touching $.4285/share. On Monday, TRXC announced the closing of $15M registered direct common share offering at $.35/share. TRXC is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery.

Economic Reports

  • On Monday, we received the ISM Non-Manufacturing Index report for June which confirmed that the US is now back in expansion mode as it came in at 57.1% well past the Mendoza line.

Investing & Inspiration

 

 

“An investment in knowledge pays the best interest.” – Benjamin Franklin.

I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates

“Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman

“The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy

“If all the economists were laid end to end, they’d never reach a conclusion.
-George Bernard Shaw

“The riskiest thing we can do is just maintain the status quo.
I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” Bob Iger, Ceo of Disney

“There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota

“Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”

“As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer

“I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban

Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner

“The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru

“The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher

“I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis

“The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton

“Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: